Effects of the Edaravone, a Drug Approved for the Treatment of Amyotrophic Lateral Sclerosis, on Mitochondrial Function and Neuroprotection
Edaravone, the first known free radical scavenger, has demonstrated cellular protective properties in animals and humans. Owing to its antioxidant activity, edaravone modulates oxidative damage in various diseases, especially neurodegenerative diseases. In 2015, edaravone was approved in Japan to tr...
Κύριοι συγγραφείς: | Sun Joo Cha, Kiyoung Kim |
---|---|
Μορφή: | Άρθρο |
Γλώσσα: | English |
Έκδοση: |
MDPI AG
2022-01-01
|
Σειρά: | Antioxidants |
Θέματα: | |
Διαθέσιμο Online: | https://www.mdpi.com/2076-3921/11/2/195 |
Παρόμοια τεκμήρια
Παρόμοια τεκμήρια
-
A New Treatment Option for Amyotrophic Lateral Sclerosis: Edaravone
ανά: Erdi Şahin
Έκδοση: (2018-03-01) -
Edaravone: A new hope for patients with amyotrophic lateral sclerosis
ανά: Shivangi Garg, κ.ά.
Έκδοση: (2019-01-01) -
Improved Long-Term Survival with Edaravone Therapy in Patients with Amyotrophic Lateral Sclerosis: A Retrospective Single-Center Study in Japan
ανά: Hideki Houzen, κ.ά.
Έκδοση: (2021-07-01) -
Long-term outcomes of edaravone in amyotrophic lateral sclerosis in South Korea: 72-week observational study
ανά: Jin-Mo Park, κ.ά.
Έκδοση: (2022-07-01) -
Cost-utility analysis for sublingual versus intravenous edaravone in the treatment of amyotrophic lateral sclerosis
ανά: Chang Liu, κ.ά.
Έκδοση: (2024-10-01)